Abstract |
Remission induction regimens for acute lymphoblastic leukemia (ALL) in adults induce complete remission (CR) in 60-90% and cure in 20-40%. A cohort study of newly diagnosed patients with ALL treated with mitoxantrone versus doxorubicin was conducted from 2005 to 2013. The primary endpoint was the proportion of CR. Eighty-five patients were included. Fifty-three received induction with doxorubicin and 32 with mitoxantrone. Median follow-up in the cohort was 40.2 months (range 2-95). Twenty-nine patients (90.6%) achieved CR in the mitoxantrone arm compared with 37 (69.8%) in the doxorubicin group (p = 0.032). There was no difference in death or relapse rate (p = 0.095 and 0.075), hematological recovery (p = 0.654), incidence of adverse events (p = 0.6), in-hospital days during induction (p = 0.456) or overall survival (p = 0.105). Induction toxicities were comparable. Mitoxantrone can be safely and effectively used as a frontline anthracycline in adults newly diagnosed with ALL.
|
Authors | José Carlos Jaime-Perez, Perla R Colunga-Pedraza, César Homero Gutiérrez-Aguirre, Mónica Andrea Pinzón-Uresti, Olga G Cantú-Rodríguez, José Luis Herrera-Garza, David Gómez-Almaguer |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 56
Issue 9
Pg. 2524-8
( 2015)
ISSN: 1029-2403 [Electronic] United States |
PMID | 25629985
(Publication Type: Journal Article)
|
Chemical References |
- Anthracyclines
- Antineoplastic Agents
- Doxorubicin
- Mitoxantrone
|
Topics |
- Adolescent
- Adult
- Aged
- Anthracyclines
(adverse effects, therapeutic use)
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Cohort Studies
- Disease-Free Survival
- Doxorubicin
(therapeutic use)
- Febrile Neutropenia
(chemically induced)
- Female
- Follow-Up Studies
- Humans
- Induction Chemotherapy
- Male
- Middle Aged
- Mitoxantrone
(adverse effects, therapeutic use)
- Mucositis
(chemically induced)
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy)
- Remission Induction
- Treatment Outcome
- Young Adult
|